^
Association details:
| Biomarker: | EGFR T790M |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Efficacy and Safety Study of Afatinib to Treat Lung Cancer Patients
Excerpt:
...L858R, exon 19 deletions, exon 20 insertions, T790M, list is...
Trial ID:
Source:
Title:
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
Excerpt:
Afatinib was active in non-small-cell lung cancer tumours that harboured certain types of uncommon EGFR mutations, especially Gly719Xaa, Leu861Gln, and Ser768Ile, but less active in other mutations types...Clinical benefit was lower in patients with de-novo Thr790Met and exon 20 insertion mutations.
DOI:
10.1016/S1470-2045(15)00026-1
Trial ID:
Source:
Title:
Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations
Excerpt:
Another biopsy was performed on a progressing liver lesion and the tissue was sent for NGS using Foundation One CDx testing. This biopsy revealed the emergence of the EGFRT790M mutation (allelic frequency of 59%)...Interestingly, this was accompanied by an increase in the allelic frequency of the L718V mutation (80%), and a decrease in the frequency of the L718Q mutation (3%)...This report suggests that while L718Q/V mutant tumors could benefit from transient responses to afatinib treatment, they can acquire the T790M mutation and eventually become resistant to all available EGFR TKIs.
DOI:
10.1158/0008-5472.CAN-19-3819
Test:
